UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DCD.C. 20549

FORM 8-K

CURRENT REPORT ~~PURSUANT~~

PURSUANT TO SECTION 13 OR 15(D) OF ~~THE~~

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August ~~April 9~~25, 2008

~~Targanta~~TARGANTA ~~Therapeutics~~THERAPEUTICS ~~Corporation~~CORPORATION

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Its~~its ~~Charter~~charter)

Delaware

Delaware

1-33730

20-3971077

(State or other jurisdiction

of incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification No.)

~~(State~~222 orThird ~~Other~~Street, ~~Jurisdiction~~Suite 2300

ofCambridge, ~~Incorporation)~~Massachusetts 02142-1122

1-33730		20-3971077
(Commission File Number)		(IRS Employer Identification No.)

(Address of Principal Executive Offices) (Zip Code)

222 Third Street, Suite 2300 Cambridge, MA		02142-1122
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 577-9020

(617) 577-9020

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~INFORMATION~~Item TO5.02. BEDeparture ~~INCLUDED~~of INDirectors ~~THE~~or ~~REPORT~~Principal Officers; Election of Directors; Appointment of Principal Officers.

~~Item~~(b) On August 725, 2008, Targanta Therapeutics Corporation (the “Company”) received notice from Jay Venkatesan that Mr.01 Venkatesan would be resigning as a member of the Board of Directors of the Company (the “Board”), effective as of August 25, 2008. Mr. ~~Regulation~~Venkatesan FDwas ~~Disclosure~~a Class II Director and a member of the Audit Committee and Compensation Committee of the Board.

On(d) ~~April~~Effective August 925, 2008, ~~Targanta~~the ~~Therapeutics~~Board ~~Corporation~~appointed ~~issued~~Stéphane Bancel as a ~~press~~director. ~~release~~Mr. Bancel ~~announcing~~was ~~that~~elected to fill the ~~United~~vacancy ~~States~~created ~~Food~~by Mr. Venkatesan’s resignation and ~~Drug~~will ~~Administration~~be ~~has~~slated ~~accepted~~to stand for ~~standard~~re-election ~~review~~at the Company’s ~~New~~2009 ~~Drug~~Annual ~~Application~~Meeting ~~for~~of ~~oritavancin for~~Stockholders. At the ~~treatment~~time of ~~complicated~~his ~~skin~~appointment ~~and~~to ~~skin~~the ~~structure~~Board, ~~infections~~Mr. Bancel ~~caused~~was byappointed ~~gram-positive~~to ~~organisms.~~serve on ~~The~~the ~~full~~Audit ~~text~~Committee of the ~~press release issued is attached as Exhibit 99~~Board.1 ~~to this Current Report on Form 8-K.~~

~~The~~Effective ~~information~~August 25, in2008, ~~this~~the ~~Form~~Board ~~8-K~~appointed ~~(including~~Rosemary ~~Exhibit 99~~A.1) ~~shall~~Crane ~~not~~as bea ~~deemed~~director. ~~“filed” for purposes of Section~~Ms. ~~18 of the Securities~~Crane ~~Exchange~~was ~~Act~~elected ofto ~~1934,~~a asterm ~~amended~~expiring (at the ~~“Exchange~~Company’s ~~Act”)~~2011 orAnnual ~~otherwise~~Meeting ~~subject to the liabilities~~ of ~~that~~Stockholders. ~~section,~~At ~~nor shall it be deemed incorporated by reference in any filing under~~ the ~~Securities~~time ~~Act~~ of ~~1933,~~her asappointment ~~amended,~~to or the ~~Exchange~~ ~~Act~~Board, ~~except~~Ms. Crane aswas ~~shall~~appointed beto ~~expressly~~serve ~~set~~on ~~forth~~the byCompensation ~~specific~~Committee ~~reference~~of inthe ~~such a filing~~Board.

~~Item~~Mr. 9Bancel and Ms.01 Crane will receive fees consistent with those fees received by the existing non-employee directors for service as a director to the Company, as described in the Company’s Definitive Proxy Statement for its 2008 Annual Meeting of Stockholders filed with the SEC on April 28, 2008. Additionally, on the date of appointment, each of Mr. ~~Financial~~Bancel ~~Statements~~and Ms. Crane was granted a non-statutory stock option to purchase 25,000 shares of common stock of the Company with an exercise price equal to $6.00 per share. Each of Mr. Bancel and ~~Exhibits~~Ms. Crane will also enter into an indemnification agreement with the Company. Such agreement is identical to the indemnification agreements the Company has previously entered into with its other directors and executive officers.

A copy of the Company’s press release announcing Ms. Crane’s and Mr. Bancel’s appointment and Mr. Venkatesan’s resignation is attached hereto as Exhibit 99.1 and the information contained therein is incorporated by reference.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

99.1 Press Release ofissued by the Company, dated ~~April~~August 926, 2008.

~~SIGNATURES~~SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TARGANTA THERAPEUTICS CORPORATION


	TARGANTA THERAPEUTICS CORPORATION

Date: August 26, 2008	By:	/s/ Daniel S. Char
	Name:	Daniel S. Char
	Title:	Vice President, General Counsel and Secretary

~~Date:~~Item ~~April~~ 9,.01 ~~2008~~Financial Statements and Exhibits.

~~By: /s/ Daniel~~(d) SExhibits. ~~Char~~

~~Daniel S~~99.1 ~~Char~~Press Release issued by the Company dated August 26, 2008.

Vice President, General Counsel and Secretary

EXHIBIT INDEX

Exhibit No.		Description of Exhibit
99.1		Press Release of the Company, dated April 9, 2008.

Filing Compare · Targanta Therapeutics Corp.